{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Free Realtime Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "currency": "SEK", "marketState": "REGULAR", "regularMarketChangePercent": -10.172407, "regularMarketPrice": 0.521, "exchange": "STO", "shortName": "Alligator Bioscience AB", "longName": "Alligator Bioscience AB (publ)", "messageBoardId": "finmb_3206363", "exchangeTimezoneName": "Europe/Stockholm", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "se_market", "esgPopulated": false, "regularMarketTime": 1684144724, "earningsTimestamp": 1689229800, "earningsTimestampStart": 1689229800, "earningsTimestampEnd": 1689229800, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.68, "epsForward": -0.13, "epsCurrentYear": -0.61, "priceEpsCurrentYear": -0.8540984, "sharesOutstanding": 363964992, "bookValue": 0.12, "fiftyDayAverage": 0.8965745, "fiftyDayAverageChange": -0.37557447, "fiftyDayAverageChangePercent": -0.41889936, "twoHundredDayAverage": 1.5056336, "twoHundredDayAverageChange": -0.98463356, "twoHundredDayAverageChangePercent": -0.65396625, "marketCap": 189625776, "forwardPE": -4.007693, "priceToBook": 4.341667, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.0 - Strong Buy", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1479888000000, "priceHint": 4, "regularMarketChange": -0.058999956, "regularMarketDayHigh": 0.636, "regularMarketDayRange": "0.501 - 0.636", "regularMarketDayLow": 0.501, "regularMarketVolume": 1802937, "regularMarketPreviousClose": 0.58, "bid": 0.523, "ask": 0.549, "bidSize": 0, "askSize": 0, "fullExchangeName": "Stockholm", "financialCurrency": "SEK", "regularMarketOpen": 0.636, "averageDailyVolume3Month": 1038593, "averageDailyVolume10Day": 1278232, "fiftyTwoWeekLowChange": 0.060500026, "fiftyTwoWeekLowChangePercent": 0.131379, "fiftyTwoWeekRange": "0.4605 - 2.75", "fiftyTwoWeekHighChange": -2.229, "fiftyTwoWeekHighChangePercent": -0.8105455, "fiftyTwoWeekLow": 0.4605, "fiftyTwoWeekHigh": 2.75, "symbol": "ATORX.ST"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Medicon Village", "address2": "ScheelevAegen 2", "city": "Lund", "zip": "223 81", "country": "Sweden", "phone": "46 4 65 40 82 00", "website": "https://www.alligatorbioscience.se", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Sweden. The company's product portfolio includes Mitazalimab, an agonistic antibody that targets CD40, which is in phase 2 clinical trail for the treatment solid metastatic tumors, initially pancreatic cancer; and ATOR-4066, a bispecific antibody tumor-specific immune effect, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage. It also offers ATOR-1017, a 4-1BB for solid metastatic tumors which is in Phase 1 clinical trial; and ALG.APV-527, which is in phase 2 clinical trail drug that target tumor-associated antigen 4-1BB and 5T4. In addition, the company develops products using its technology platforms, including ALLIGATOR-GOLD and ALLIGATOR-FAB, a proprietary human antibody library that contains approximately 60 billion unique antibody fragments; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and RUBY, a bispecific antibody format. Further, it has collaboration and out-licensing agreements with Aptevo Therapeutics, Inc.; Orion Corporation.; MacroGenics, Inc.; Biotheus; and Abclon. The company was incorporated in 2000 and is headquartered in Lund, Sweden.", "fullTimeEmployees": 58, "companyOfficers": [{"maxAge": 1, "name": "Mr. S\u00f8ren  Bregenholt Ph.D.", "age": 51, "title": "Chief Exec. Officer", "yearBorn": 1971, "fiscalYear": 2022, "totalPay": {"raw": 4400000, "fmt": "4.4M", "longFmt": "4,400,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Marie  Svensson", "age": 58, "title": "Chief Financial Officer", "yearBorn": 1964, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Malin  Carlsson", "age": 54, "title": "Head of R&D, Exec. VP & COO", "yearBorn": 1968, "fiscalYear": 2021, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Laura  von Schantz", "age": 40, "title": "Chief Technology Officer", "yearBorn": 1982, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Peter  Ellmark Ph.D.", "age": 49, "title": "Chief Scientific Officer", "yearBorn": 1973, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Julie  Silber", "title": "Director of Communications & Investor Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Sumeet  Ambarkhane M.D.", "title": "Chief Medical Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}